Retinal Blood Flow as a Predictor of Recurrence of Macular Edema After Intravitreal Ranibizumab Injection in Central Retinal Vein Occlusion
Takano Y, Noma H, Yasuda K, Yamaguchi T, Goto H, Shimura M

Disclaimer:
Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to the content.

Copyright:
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

© The Author(s). Published by S. Karger AG, Basel
Research Article
Retinal Blood Flow as a Predictor of Recurrence of Macular Edema After Intravitreal Ranibizumab Injection in Central Retinal Vein Occlusion

Yurika Takano, Hidetaka Noma, Kanako Yasuda, Tomoe Yamaguchi, Hiroshi Goto, Masahiko Shimura

a Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan
b Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan

Short Title: Retinal blood flow and recurrence in CRVO

Corresponding Author:
Hidetaka Noma
Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University
1163, Tatemachi, Hachioji, Tokyo 193-0998, Japan
Tel: 81-42-665-5611
E-mail: noma-hide@umin.ac.jp

Number of Tables: 2
Number of Figures: 4
Word count: 2851
Keywords: retinal blood flow, laser speckle flowgraphy, macular edema, recurrence, central retinal vein occlusion

Abstract
Introduction: To investigate the relationship between retinal blood flow and the presence or absence of macular edema (ME) recurrence after intravitreal ranibizumab injection (IRI) in patients with central retinal vein occlusion (CRVO).
Methods: We reviewed the medical records of 16 eyes with ME associated with CRVO. All eyes had received pro re nata IRI. Repeat IRI was performed if the central macular thickness was greater than or equal to 300 µm. At 12 months, patients without additional IRI in the past 6 months were assigned to the resolved group; and those with additional IRI, to the recurrence group. We used laser speckle flowgraphy (LSFG) to measure the mean blur rate (MBR) of the optic disc before and after IRI.
Results: Ten of the 16 eyes were assigned to the resolved group, and the other 6 eyes, to the recurrence group. At several visits in the 12 months after IRI, MBR was significantly higher in the resolved group than in the recurrence group. Percent change of MBR (%MBR) from baseline was significantly higher in the resolved group than in the recurrence group at 1 month (initial %MBR) and 11 and 12 months. Multivariate stepwise analysis showed that the initial %MBR was significantly and negatively correlated with the number of IRIs.
Discussion/Conclusion: These findings suggest that determining %MBR in LSFG may be a useful way to determine the likelihood of ME recurrence in CRVO patients.
Introduction
Central retinal vein occlusion (CRVO) is common in patients with lifestyle-related diseases such as hypertension and arteriosclerosis. Macular edema occurs frequently in CRVO and is the main cause of visual impairment in this disorder. Progression of ischemia in CRVO can result in neovascular glaucoma, a relevant risk factor that causes rapid vision loss and has a poor prognosis [1]. In CRVO, the retinal central vein is compressed by an arteriosclerotic central retinal artery in the vicinity of the lamina cribrosa, leading to venous thrombosis [2]. In the acute phase of CRVO, pressure increases in the capillaries and venules affected by the obstruction, which results in breakdown of the blood-retinal barrier and leakage of blood components into the eye. In macular edema, fluid accumulates in the inner to outer plexiform layer in the retina, perhaps because of an alteration of retinal blood flow [3]. CRVO leads to increased resistance to blood flow in retinal arterioles, causing closure of retinal capillaries and small arterioles and resulting in retinal hypoxia [4]. Thus, understanding the retinal hemodynamic abnormalities that underlie the pathogenesis of CRVO is of critical importance.

Laser speckle flowgraphy (LSFG) is a noninvasive, real-time method that can measure the relative blood flow of the optic nerve head [5, 6]. Matsumoto et al. recently reported that blood flow changes after anti-vascular endothelial growth factor (VEGF) therapy [7], and novel findings from Cehofski et al. based on proteomic studies indicate that VEGF regulates a number of proteins involved in formation of macular edema in retinal vein occlusion [8]. Induction of VEGF by vascular occlusion was shown to be associated with macular edema with CRVO [9]. Clinical trials on anti-VEGF therapy have led to the approval of its use as a treatment for macular edema with CRVO. Several randomized clinical trials have demonstrated better visual prognosis, represented as a 12- to 13-letter gain from baseline, with repeated intravitreal anti-VEGF therapy for macular edema associated with CRVO. However, the required number of anti-VEGF injections was 12 to 13 per 2-year period [10-12]. Furthermore, unclear is whether retinal blood flow is involved in the recurrence of macular edema. Therefore, we evaluated retinal blood flow before and after anti-VEGF therapy in patients with CRVO and examined the relationship between retinal blood flow and the presence or absence of recurrence of macular edema in these patients.

Materials and Methods
Subjects
This retrospective study was conducted in accordance with the Declaration of Helsinki. After approval by the Review Committee of the Institutional Research Board of Tokyo Medical University Hachioji Medical Hospital, consecutive CRVO patients with macular edema were enrolled in the study and underwent intravitreal ranibizumab injection (IRI) (Lucentis; 0.5 mg in 0.05 ml; Genentech, Inc., South San Francisco, CA) at Tokyo Medical University Hachioji Medical Hospital. After obtaining informed consent from the patients, an IRI was performed via the pars plana using a 30-gauge needle. Injections were performed at 3.5 mm posterior to the limbus.
Patients with CRVO who were scheduled to undergo IRI for treatment of macular edema between June 2015 and July 2019 were eligible for the study. CRVO was diagnosed by fluorescein angiography with a Digital Retinal Camera CF-1 (Canon, NY, USA). Criteria for receiving IRI were macular edema involving the fovea (central macular thickness [CMT] > 300 μm) and a best-corrected visual acuity (BCVA) of less than 25/30. Patients were evaluated every month for 12 months, and IRI was repeated if the CMT was greater than or equal to 300 μm and after obtaining consent from the patient. At 12 months, patients without additional IRI in the past 6 months were assigned to the resolved group, and those with additional IRI in that timeframe, to the recurrence group. Patients were excluded if proper measurements could not be obtained (e.g., in case of a refractive error of less than -6.0 diopters, corneal opacity, poor mydriasis, cataracts with severe opacity, or vitreous hemorrhage) and if they had been followed up for less than 12 months. Additional exclusion criteria were a diagnosis of ischemic CRVO, glaucoma, aphakia, rubeosis iridis, diabetes mellitus with diabetic retinopathy, or ocular infection; previous ocular inflammation, macular laser photoocoagulation, intravitreal injection of anti-VEGF agents, treatment with steroids, or vitreoretinal surgery; and concomitant administration of anti-inflammatory comedication.

LSFG Blood Flow Measurements
LSFG was performed at baseline and at every visit after IRI. The MBR, obtained by LSFG (LSFG-NAVI; Softcare Co, Ltd, Fukuoka, Japan), is a quantitative index of the relative blood flow velocity, as reported in detail previously [5, 6, 13]. By using offline analysis software (LSFG Analyzer, version 3.0.47.0), we combined all images and converted
them to color-coded maps in which each pixel was assigned a computed MBR. The MBR was expressed in arbitrary units (AU) and displayed as a 2-dimensional, color-coded map of blood flow velocity. After manually defining a circle around the optic disc with a rubber band [14-16], we investigated the MBR within this region. We fitted an elliptical band around the optic disc, so measurements of MBR within the region were not affected by the vessel tortuosity. Therefore, we were able to measure MBR in all patients. The MBR in the optic disc area includes choroidal blood flow; therefore, to exclude any influence of choroidal blood flow on retinal blood flow in the major vessels (arteries and veins) we subtracted the mean MBR of the tissue area from that of the vascular area [7, 17]. All measurements were performed in triplicate, and the mean MBR value was calculated. Eye positions were recorded by performing LSFG with an auto-tracking function, which enabled us to capture the same area again during subsequent examinations with high reproducibility. To evaluate changes of retinal blood flow, we calculated the percent change of MBR (%Δ MBR) from baseline, as follows: %Δ MBR = (MBRreach month − MBRbaseline) / MBRbaseline × 100, where MBRbaseline and MBRreach month were the levels of MBR corresponding to the MBR at baseline and at each month after the initial IRI, respectively. All blood flow measurements were performed before intravitreal injection.

Routine examinations
Each month, in addition to LSFG, all patients underwent a complete ophthalmic examination, including decimal BCVA and spectral-domain optical coherence tomography (OCT) with the Spectralis imaging platform (Heidelberg Engineering, Heidelberg, Germany). At each follow-up, we determined BCVA and performed OCT. The CMT was defined as the distance between the inner limiting membrane and the retinal pigment epithelium (including any serous retinal detachment) and was automatically measured by computer software. For statistical analysis, BCVA was converted to the logarithm of the minimal angle of resolution (logMAR) scale.

Hemodynamics
In healthy people with normal eyes, the relationship between MBR and ocular perfusion pressure (OPP) is bilinear within a certain range [18]. Therefore, to exclude physiological responses from the present results we calculated the OPP on the basis of blood pressure and intraocular pressure (IOP). First, we calculated mean blood pressure (MBP) from systolic blood pressure (SBP) and diastolic blood pressure (DBP) as MBP = DBP + 1/3(SBP−DBP). Then, we calculated OPP by using the following equation: OPP = 2/3MBP − IOP.

Statistical Analysis
All analyses were performed with SAS System 9.4 software (SAS Institute Inc., Cary, North Carolina, USA). Results are presented as the mean ± SD. We compared unpaired continuous variables with an unpaired Student’s t test and paired continuous variables with a paired Student’s t test. A multivariable linear regression model with stepwise variable selection after log transformation was performed to determine the influence of the various factors. Two-tailed p values of less than 0.05 were considered to indicate a significant difference.

Results
A total of 16 consecutive patients with CRVO (16 eyes) were eligible to be included in the study (11 men and 5 women), with a mean age of 69.3 ± 13.8 years. None of these patients had any previous treatments for macular edema related to CRVO. The mean duration of macular edema was 25.8 ± 8.7 days (range, 14-47 days). Fourteen of the 16 patients (87.5%) had hypertension, which was defined as current treatment with antihypertensive drugs or a blood pressure greater than 140/90 mmHg, and 5 of the 16 patients (31.3%) had hyperlipidemia. The mean SBP was 137 ± 9.5 mmHg; mean DBP, 85 ± 9.1 mmHg; MBP, 102 ± 7.7 mmHg; and OPP, 87 ± 7.6 mmHg. The mean baseline BCVA was logMAR 0.60 ± 0.49; mean baseline CMT, 811 ± 260 μm; and mean baseline MBR, 18.8 ± 5.95 AU. Both BCVA (logMAR 0.20 ± 0.37) and CMT (253 ± 64.7 μm) improved significantly at 12 months after initial IRI in all eyes (P < 0.001 and P < 0.001, respectively), but the mean MBR was not significantly different between baseline and 12 months (21.1 ± 8.69 AU; P = 0.137). In addition, we found no cases of conversion from the nonischemic to the ischemic type of CRVO during the 12 months.

At 12 months after initial IRI, 10 of the 16 eyes (62.5%) with macular edema associated with CRVO had required no additional IRI in the past 6 months. These 10 eyes were assigned to the resolved group, and the other 6 eyes (37.5%), to the recurrence group. The clinical characteristics of the two groups are summarized in Table 1. We found no significant differences in the sex distribution or baseline values of any clinical parameters (duration of
macular edema, hypertension, SBP, DBP, hyperlipidemia, BCVA, CMT, MAP, OPP, and MBR) between the resolved and recurrence groups, but age was significantly different between the two groups (P = 0.012) (Table 1). BCVA improved significantly more in the resolved group than in the recurrence group at each month (3 months, *P = 0.008; 5 months, *P = 0.036; 6 months, *P = 0.007; 7 months, *P = 0.021; 9 months, *P = 0.049; 10 months, *P = 0.025; 11 months, *P = 0.009; and 12 months, *P = 0.023) (Figure 1A). CMT decreased significantly more in the resolved group than in the recurrence group at 4 months (*P = 0.047) and 6 months (*P = 0.002) (Figure 1B).

The MBR was significantly higher in the resolved group than in the recurrence group at each month (1 month, *P = 0.013; 2 months, *P = 0.017; 3 months, *P = 0.038; 4 months, *P = 0.018; 8 months, *P = 0.022; 9 months, *P = 0.025; 10 months, *P = 0.030; 11 months, *P = 0.017; and 12 months, *P = 0.004) (Figure 2A). The %MBR from baseline was significantly higher in the resolved group than in the recurrence group at 1 month (initial %MBR) (*P = 0.010), 11 months (*P = 0.017), and 12 months (*P < 0.001) (Figure 2B).

At 12 months, the number of times IRI had been performed was as follows: once, 4 eyes; twice, 5 eyes; three times, 2 eyes; four times, 2 eyes; and five or more times, 3 eyes. The mean number of IRIs was significantly higher in the recurrence group than in the resolved group (5.0 ± 1.5 vs 1.7 ± 0.67, respectively; *P < 0.001). Table 2 shows the associations of the number of IRIs with clinical characteristics. In all eyes and patients, the initial %MBR was significantly and negatively correlated with the number of IRIs and age was significantly correlated with the number of IRIs. Only the initial %MBR was identified as a significant factor in the stepwise multivariable analysis.

Discussion/Conclusion
In this study, we evaluated whether retinal blood flow is involved in the recurrence of macular edema by measuring retinal blood flow before and after anti-VEGF therapy in patients with CRVO and examining the relationship between retinal blood flow and the presence or absence of recurrence of macular edema in these patients. The percent change of MBR (%MBR) from baseline was significantly higher in the resolved group than in the recurrence group at 1 month (initial %MBR) and 11 and 12 months. In addition, multivariate analysis showed that the initial %MBR was significantly and negatively correlated with the number of IRIs during the 12-month study period. These findings suggest that the better the initial improvement in retinal blood flow after anti-VEGF therapy, the less likely recurrence of macular edema is.

Previously, development of macular edema in patients with CRVO was hypothesized to be caused by movement of fluid from the vascular compartment to the tissues (Starling’s Law) after breakdown of the blood-retinal barrier [19, 20]. This hypothesis is supported by the finding that a decrease of retinal blood flow may lead to stagnation of retinal blood flow and subsequent recurrence of macular edema [21]. Taken together with the present findings, such reports confirm that recurrence of macular edema after IRI might be due to a decrease or stagnation of retinal blood flow. In addition, higher MBR indicates lower vascular resistance and better compensation, which would lead to less retinal ischemia and hypoxia. Therefore, a change of MBR, as measured by LSFG, could be an indicator of recurrence of macular edema.

We found that age was significantly different between the two groups and was significantly correlated with the number of IRIs. Advanced age is a known risk factor for CRVO [22, 23], and age also was shown to be a risk factor for CRVO among those receiving bevacizumab therapy [7]. Because vascular endothelial cell damage becomes more severe in older age [24], macular edema might be more likely to recur because of damage to tight junctions [25]. These results suggest that older patients with CRVO have a higher risk of recurrence of macular edema, and they are supported by our finding that recurrence of macular edema was significantly associated with age. Thus, age might be a useful indicator of necessary treatment intensity.

We also found that the final visual acuity was significantly different between the resolved and recurrence groups, although we found no significant difference in CMT between the groups at the final visit. Earlier studies showed that visual acuity is strongly correlated with the integrity of the photoreceptors [26, 27]. In CRVO, each recurrence of macular edema could cause further damage to photoreceptors, which might explain why the final visual acuity was significantly different between the two groups. In the case of older patients or lack of improvement of blood flow after anti-VEGF therapy, switching to another treatment may be the best approach because of the possibility of recurrence of macular edema.

The present study was limited by the small sample size, which meant that we compared only 10 patients in the resolved group with 6 patients in the recurrence group. Nevertheless, we found that change in retinal blood flow may influence the number of IRIs required in eyes with CRVO. Further studies in larger samples are required to clarify the relationship between retinal blood flow and recurrence of macular edema. If confirmed, our results may indicate that LSFG could potentially save some follow-up visits for some patients with CRVO because high
MBR may predict a favorable outcome. In addition, the clinical pictures of nonischemic and ischemic CRVO are generally quite different [28], which is why we excluded patients with ischemic CRVO from this study. Consequently, patients with neovascular glaucoma, panretinal photocoagulation, and severe loss of visual acuity were also excluded. Further studies are required to compare retinal blood flow and recurrence of macular edema in nonischemic and ischemic CRVO.

In conclusion, we found that the %MBR from baseline was significantly higher in the resolved group than in the recurrence group at 1 month (initial %MBR) and 11 and 12 months. The initial %MBR significantly and negatively correlated with the number of IRIs for macular edema associated with CRVO. Therefore, determining the percent change of MBR when measuring LSFG may be a useful way to determine the likelihood of recurrence of macular edema in eyes with CRVO.
Acknowledgement
We thank Katsunori Shimada (Department of Biostatistics, STATZ Corporation, Tokyo) for assistance with the statistical analysis.

Statement of Ethics
This study was conducted at the Department of Ophthalmology of Tokyo Medical University Hachioji Medical Center and approval was obtained from Institutional Review Board of Tokyo Medical University Hachioji Medical Center (IRB No. H-132). The procedures of the study conformed to the tenets of the Declaration of Helsinki and all patients gave written informed consent before enrollment.

Conflict of Interest Statement
No conflicting relationship exists for any author.

Funding Sources
None.

Author contributions
H.N., and M.S. were involved in the design and conduct of the study. Collection and management of the data were done by Y.T., T.Y., and H.N., while analysis and interpretation of the data were performed by K.Y., and M.S.. Preparation of the first draft of the manuscript was done by Y.T., and H.N., and review and approval of the manuscript was performed by H.G., and M.S.. All authors have read and approved the final manuscript.

Data Availability Statement
The data that support the findings of this study are not publicly available because they contain information that could compromise the privacy of research participants and because ethics committee approval for release of the data was not obtained.
Figure Legends

Fig 1. Best-corrected visual acuity and central macular thickness after intravitreal ranibizumab injection. (A) Best-corrected visual acuity improved more in the resolved group (solid line) than in the recurrence group (dotted line) at several visits (baseline, $P = 0.316$; 1 month, $P = 0.168$; 2 months, $P = 0.107$; 3 months, $P = 0.008$; 4 months, $P = 0.061$; 5 months, $P = 0.036$; 6 months, $P = 0.007$; 7 months, $P = 0.021$; 8 months, $P = 0.067$; 9 months, $P = 0.049$; 10 months, $P = 0.025$; 11 months, $P = 0.009$; and 12 months, $P = 0.023$). (B) Central macular thickness showed a significant difference between the resolved group (solid line) and recurrence group (dotted line) only at 4 and 7 months (baseline, $P = 0.111$; 1 month, $P = 0.273$; 2 months, $P = 0.090$; 3 months, $P = 0.206$; 4 months, $P = 0.047$; 5 months, $P = 0.368$; 6 months, $P = 0.002$; 7 months, $P = 0.205$; 8 months, $P = 0.053$; 9 months, $P = 0.129$; 10 months, $P = 0.065$; 11 months, $P = 0.054$; and 12 months, $P = 0.455$). BCVA log MAR, best-corrected visual acuity converted to the logarithm of minimal angle of resolution; CMT, central macular thickness.

Fig 2. Mean blur rate and percent change of mean blur rate after intravitreal ranibizumab injection. (A) Mean blur rate was significantly higher in the resolved group (solid line) than in those in the recurrence group (dotted line) at several visits (baseline, $P = 0.417$; 1 month, $P = 0.013$; 2 months, $P = 0.017$; 3 months, $P = 0.038$; 4 months, $P = 0.018$; 5 months, $P = 0.108$; 6 months, $P = 0.241$; 7 months, $P = 0.074$; 8 months, $P = 0.022$; 9 months, $P = 0.025$; 10 months, $P = 0.030$; 11 months, $P = 0.017$; and 12 months, $P = 0.004$). (B) Percent change in mean blur rate was significantly higher in the resolved group (solid line) than in the recurrence group (dotted line) at 1 month and 11 and 12 months (1 month, $P = 0.010$; 2 months, $P = 0.081$; 3 months, $P = 0.194$; 4 months, $P = 0.051$; 5 months, $P = 0.148$; 6 months, $P = 0.480$; 7 months, $P = 0.118$; 8 months, $P = 0.089$; 9 months, $P = 0.077$; 10 months, $P = 0.264$; 11 months, $P = 0.017$; and 12 months, $P < 0.001$). MBR, mean blur rate; %MBR, percent change of MBR.
Table 1. Baseline Clinical Features of the Resolved and Recurrence Groups

<table>
<thead>
<tr>
<th>Findings</th>
<th>Resolved group (N=10)</th>
<th>Recurrence group (N=6)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.7 ± 14.4(^\dagger)</td>
<td>80.1 ± 2.3(^\dagger)</td>
<td>0.012</td>
</tr>
<tr>
<td>Gender (female/male)</td>
<td>2/8</td>
<td>3/3</td>
<td>0.210</td>
</tr>
<tr>
<td>Duration of macular edema (days)</td>
<td>25.5 ± 7.27(^\dagger)</td>
<td>26.2 ± 12.1(^\dagger)</td>
<td>0.892</td>
</tr>
<tr>
<td>Hypertension</td>
<td>8</td>
<td>6</td>
<td>0.242</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic Blood pressure (mmHg)</td>
<td>135 ± 11(^\dagger)</td>
<td>140 ± 7.6(^\dagger)</td>
<td>0.345</td>
</tr>
<tr>
<td>Diastolic Blood pressure (mmHg)</td>
<td>87 ± 7.4(^\dagger)</td>
<td>80 ± 11(^\dagger)</td>
<td>0.130</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>3</td>
<td>2</td>
<td>0.889</td>
</tr>
<tr>
<td>Baseline BCVA (logMAR)</td>
<td>0.50 ± 0.50(^\dagger)</td>
<td>0.77 ± 0.48(^\dagger)</td>
<td>0.316</td>
</tr>
<tr>
<td>Baseline CMT (μm)</td>
<td>730 ± 167(^\dagger)</td>
<td>945 ± 342(^\dagger)</td>
<td>0.111</td>
</tr>
<tr>
<td>MBP (mmHg)</td>
<td>103 ± 6.9(^\dagger)</td>
<td>100 ± 9.7(^\dagger)</td>
<td>0.443</td>
</tr>
<tr>
<td>OPP (mmHg)</td>
<td>89 ± 6.1(^\dagger)</td>
<td>85 ± 10(^\dagger)</td>
<td>0.374</td>
</tr>
<tr>
<td>Baseline MBR (AU)</td>
<td>19.8 ± 5.51(^\dagger)</td>
<td>17.2 ± 6.83(^\dagger)</td>
<td>0.417</td>
</tr>
</tbody>
</table>

BCVA=best-corrected visual acuity; CMT=central macular thickness; log MAR=logarithm of the minimum angle of resolution; MBP=mean blood pressure; MBR=mean blur rate; OPP=ocular perfusion pressure; AU=arbitrary units; \(^\dagger\)Mean ± standard deviation (SD).
Table 2. Linear regression analysis of factors related to number of intravitreal ranibizumab injections

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate</th>
<th>Multivariate stepwise</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Correlation coefficient</td>
<td>p value</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>0.50</td>
<td>0.048</td>
</tr>
<tr>
<td>Duration of macular edema (days)</td>
<td>-0.21</td>
<td>0.427</td>
</tr>
<tr>
<td>Baseline BCVA (log MAR)</td>
<td>0.32</td>
<td>0.221</td>
</tr>
<tr>
<td>Baseline CMT (μm)</td>
<td>0.44</td>
<td>0.088</td>
</tr>
<tr>
<td>Baseline MBR (AU)</td>
<td>-0.13</td>
<td>0.624</td>
</tr>
<tr>
<td>%Δ MBR (%) (1 month from baseline)</td>
<td>-0.63</td>
<td>0.009</td>
</tr>
</tbody>
</table>

BCVA=best-corrected visual acuity; CMT=central macular thickness; log MAR=logarithm of the minimum angle of resolution; MBR= mean blur rate; AU= arbitrary units.